id: NEW:sglt2_inhibitor_treatment_access_to_kidney_disease
name: SGLT2 Inhibitor Treatment Access â†’ Chronic Kidney Disease
from_node:
  node_id: NEW:sglt2_inhibitor_treatment_access
  node_name: SGLT2 Inhibitor Treatment Access
to_node:
  node_id: kidney_disease
  node_name: Chronic Kidney Disease
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Healthcare systems adopt SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin) as
  standard treatment for CKD'
- 'Step 2: SGLT2 inhibitors reduce glucose reabsorption in proximal tubules, lowering intraglomerular
  pressure'
- 'Step 3: Reduced glomerular hyperfiltration slows progression of kidney damage'
- 'Step 4: Anti-inflammatory and cardioprotective effects provide additional renal protection'
- 'Step 5: Disease progression to end-stage renal disease is delayed or prevented'
evidence:
  quality_rating: A
  n_studies: 13
  primary_citation: 'Anh Thi Ngoc Toan et al. 2024. "Cost-effectiveness of sodium-glucose cotransporter
    2 inhibitors in the treatment of chronic kidney disease: a systematic review." https://doi.org/10.1080/14737167.2024.2420654'
  supporting_citations:
  - Studies evaluating Empagliflozin (n=3) - specific citations require full-text access
  - Studies evaluating Canagliflozin (n=3) - specific citations require full-text access
  - Studies evaluating Dapagliflozin (n=8) - specific citations require full-text access
  doi: 10.1080/14737167.2024.2420654
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: SGLT2 inhibitors added to standard of care provide cost-effective treatment for CKD patients
  regardless of T2D status, with cost-saving benefits in CKD patients with T2D in high-income countries.
  This represents a healthcare system intervention that can reduce disease progression and economic burden.
spatial_variation:
  varies_by_geography: true
  variation_notes: Cost-effectiveness findings varied by country income level; SGLT2 inhibitors were cost-saving
    in high-income countries under health system perspective
moderators:
- name: type_2_diabetes_status
  direction: strengthens
  strength: strong
  description: In CKD patients with T2D, SGLT2 inhibitors were cost-saving rather than just cost-effective
- name: country_income_level
  direction: strengthens
  strength: moderate
  description: Cost-saving benefits were observed primarily in high-income countries under health system
    perspective
- name: specific_sglt2_agent
  direction: varies
  strength: moderate
  description: Dapagliflozin was not cost-effective compared to Canagliflozin, suggesting differential
    value between agents
structural_competency:
  equity_implications: This mechanism highlights healthcare system-level determinants of CKD outcomes.
    Access to SGLT2 inhibitors depends on healthcare coverage, formulary inclusion, and affordability
    policies. The finding that cost-effectiveness varies by country income level suggests structural economic
    factors influence treatment access. Equity implications include that patients in lower-income settings
    may not have access to these beneficial treatments, and within-country disparities in insurance coverage
    could create differential access to these medications.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.925626'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
